Thymalin Research Guide — Thymic Peptide Bioregulator, Immunosenescence Biology & T-Cell Restoration Data (2026)
- Thymalin is a thymic peptide bioregulator developed by Vladimir Khavinson and Vyacheslav Morozov at the St. Petersburg Institute of Bioregulation and Gerontology, originally isolated from bovine calf thymus tissue in 1981 as a polypeptide complex. The active components were subsequently identified through fractionation as short peptides, predominantly the dipeptide L-Glu-L-Trp (L-glutamyl-L-tryptophan; also known as Thymogen®), which represents the minimal active thymic sequence. In research contexts, “Thymalin” may refer to either the original bovine polypeptide complex or the synthetic Glu-Trp dipeptide form; researchers should confirm the specific form in the COA documentation. YPB offers research-grade Thymalin as YPB.280 (Research Use Only).
- Mechanism: Thymalin targets thymic tissue function with the goal of restoring age-impaired T-cell maturation and output. The proposed mechanism involves modulation of gene expression in thymic epithelial cells and thymocytes, promoting T-cell differentiation through the DN (double-negative) → DP (double-positive) → SP (single-positive CD4+ or CD8+) developmental stages. Downstream effects in Khavinson group publications include improved CD3+, CD4+, CD4/CD8 ratio, and NK cell activity in aged subjects, consistent with partial restoration of thymic output and immune competence.
- The immunosenescence context: the thymus undergoes progressive involution with age, retaining only approximately 15% of peak functional tissue volume by age 50 and continuing to decline. This thymic involution directly reduces naive T-cell output, narrows T-cell receptor (TCR) repertoire diversity, and impairs adaptive immune responses to new antigens. Restoring thymic T-cell production is a primary research target in immunosenescence biology.
- Key evidence: Khavinson & Morozov (2002, PMID: 12577695; 2003, PMID: 14523363) — long-term human studies (6–8 year follow-up) in elderly subjects reporting mortality reduction and improved immune parameters with combined Thymalin + Epitalon protocols. Same single-institute caveat as all Khavinson group data applies. No independent large-scale RCT as of April 2026.
- Key distinction from Thymosin Alpha-1: Thymalin targets upstream thymic organ function (promoting T-cell production at source); Thymosin Alpha-1 (28 AA; from thymosin fraction 5) directly activates mature immune effector cells (T cells, NK cells, dendritic cells) downstream. Complementary mechanisms. YPB.280. Updated April 2026.
What Is Thymalin and What Makes It Different From Other Thymic Peptides?
Immunosenescence Research
Upstream Thymic Function vs. Downstream Immune Activation
Thymalin is the thymus-targeted member of the Khavinson peptide bioregulator system — a research framework developed at the St. Petersburg Institute of Bioregulation and Gerontology that proposes short peptides derived from specific organs can restore the biological function of those organs when they decline with age. Updated April 2026. Each compound in the Khavinson system targets a different organ: Epitalon (pineal gland; telomerase/circadian); Pinealon (CNS neuroprotection); Thymalin (thymus; T-cell immune function). Thymalin was originally prepared as a polypeptide complex from bovine calf thymus tissue, containing a heterogeneous mixture of short peptides (2–8 amino acids; MW 1,000–10,000 Da). Through subsequent fractionation analysis, the key active component was identified as the dipeptide L-Glu-L-Trp (L-glutamyl-L-tryptophan; MW ~332 Da), which was developed into the compound Thymogen® approved in Russia.
When researchers and white-label brands encounter “Thymalin” in research peptide catalogs, the compound is typically either (1) the synthetic Glu-Trp dipeptide (the identified active component) or (2) a standardized polypeptide complex preparation. Researchers should verify which form is specified in the COA documentation, as the two have different MW profiles and potentially different activity breadth.
Key Characteristics
| Parameter | Value |
|---|---|
| Origin | Originally isolated from bovine calf thymus (polypeptide complex; Morozov & Khavinson, 1981); active component: L-Glu-L-Trp dipeptide |
| Active Dipeptide | L-Glu-L-Trp (L-glutamyl-L-tryptophan); Thymogen® in compound form; MW ~332 Da |
| YPB SKU | YPB.280 |
| System Classification | Khavinson peptide bioregulator family; thymus-targeted; alongside Epitalon (pineal), Pinealon (CNS), Cortagen (adrenal) |
| Primary Mechanism | Thymic tissue gene expression modulation → T-cell differentiation and maturation support; thymocyte development through DN → DP → SP stages; downstream: improved CD3+, CD4+, CD4/CD8 ratio, NK cell activity |
| Research Target | Immunosenescence; thymic involution; T-cell repertoire narrowing; age-related immune decline; T-cell differentiation biology |
| Mechanism Level | Upstream (thymic organ function) — distinct from Thymosin Alpha-1 (downstream; mature immune cell activation) |
| Half-Life | Short (dipeptide; rapid degradation in circulation); research protocols use short courses rather than continuous administration |
| FDA Status | Not FDA-approved for human use. Investigational/research compound (RUO). Thymogen® (Glu-Trp) approved in Russia. Research Use Only (RUO) in international research context. |
| WADA Status | Not listed on WADA Prohibited List 2025 |
| Evidence Base | Primarily Khavinson group (St. Petersburg); single-institute; limited independent international replication; no FDA-standard RCT as of April 2026 |
| Storage | Lyophilized: −20°C. Reconstituted: 2–8°C, use within 14 days. |
The Immunosenescence Problem: Why Thymic Involution Drives Immune Aging
To understand Thymalin’s research rationale, it is necessary to understand why the thymus — not circulating immune cells — is the bottleneck for adaptive immune competence in aging.
Thymic Involution: The Root of Immunosenescence
The thymus is the primary lymphoid organ where T-cell precursors (from bone marrow) undergo selection, education, and maturation before entering circulation as functional naïve T cells. Thymic involution — the progressive replacement of functional thymic tissue with adipose tissue — begins in early adulthood and accelerates after puberty. By age 50, most adults retain only approximately 15% of peak thymic functional volume. By age 70, thymic output of naïve T cells has declined by approximately 95% vs. young adult levels.
The consequence of this collapse in thymic output is immunosenescence: a multi-dimensional immune aging phenotype characterized by (1) narrowing of T-cell receptor (TCR) repertoire diversity as the naïve T-cell pool is not replenished; (2) accumulation of exhausted and senescent T cells that occupy the peripheral T-cell compartment without providing productive immune responses; (3) impaired responses to new antigens (pathogens not previously encountered, neoantigens, vaccination); (4) expansion of regulatory T cells (Tregs) that suppress immune responses; and (5) elevated pro-inflammatory signaling (inflammaging) from dysfunctional immune cells.
T-Cell Differentiation Stages Thymalin Targets
T-cell development in the thymus proceeds through defined stages marked by surface antigen expression. Precursor cells enter the thymic cortex as DN (double-negative; CD4−CD8−) thymocytes, progress through DN1→DN2→DN3→DN4 stages involving TCR gene rearrangement (V(D)J recombination), then become DP (double-positive; CD4+CD8+) thymocytes where TCR selection occurs: positive selection (TCRs that can recognize self-MHC) and negative selection (deletion of self-reactive TCRs that would cause autoimmunity). Selected DP cells differentiate into SP (single-positive) naïve T cells: CD4+ helper T cells (MHC class II restricted) or CD8+ cytotoxic T cells (MHC class I restricted), which then exit to the periphery. Thymalin’s proposed mechanism targets thymic epithelial cell gene expression and thymocyte maturation support to increase the throughput and efficiency of this process in aged thymic tissue.
What Research Applications Has Thymalin Been Studied For?
Immunosenescence and Thymic Restoration Research
The primary published application is studying thymic function restoration in aged animal models and elderly human subjects. Khavinson group publications document improved T-cell parameters (CD3+, CD4+, CD4/CD8 ratio, NK cell activity) in elderly subjects receiving Thymalin as part of combination bioregulator protocols. The proposed mechanism — direct modulation of thymic epithelial cell gene expression patterns to restore thymocyte maturation support — is supported by in vitro data from Khavinson group cell culture studies but has not been independently replicated by international research groups as of April 2026.
Longevity and Mortality Research
Khavinson and Morozov (2002, PMID: 12577695; 2003, PMID: 14523363) published long-term follow-up data (6–8 years) from elderly subjects receiving Thymalin + Epitalon combination protocols, reporting significant decreases in mortality and improvements in immune and endocrine function markers vs. control groups. These are the most clinically significant published data points for Thymalin but carry the same single-institute, non-independently-replicated evidence limitation as all Khavinson group human studies.
COVID-19 / Acute Immune Restoration Research
A study published in PMC (2021, PMC8654498) examined Thymalin use in severe COVID-19 elderly research subjects with lymphopenia. The Thymalin group demonstrated faster reversal of lymphopenia with recovery in CD4+, CD3+HLA-DR+, B-cell, and NK-cell populations vs. control, suggesting thymic peptide bioregulation may accelerate lymphocyte recovery in acute immunocompromised states beyond just chronic age-related immune decline.
Carcinogenesis Prevention Research (Glu-Trp / Thymogen)
A Khavinson group study (Biogerontology) examined the Glu-Trp dipeptide (the active Thymalin component) in female rats over 12 months of SC administration, reporting reduced spontaneous tumor incidence and improved survival vs. saline-injected controls. The proposed mechanism involves immune surveillance enhancement through T-cell competence restoration, reducing the immune editing escape that allows tumor cells to proliferate. This represents a mechanistic link between thymic immune function and cancer immunosurveillance.
What Does the Research Data Show?
| Study / Context | Design | Key Finding & Adverse Events | Year |
|---|---|---|---|
| Khavinson & Morozov — Geroprotective effect | Long-term follow-up (6–8 years) / elderly subjects / Thymalin + Epitalon combination | Significant mortality decrease in peptide-treated groups vs. controls; improved immune function (T-cell parameters) and endocrine markers; evidence for thymic and pineal function restoration in elderly. (Adv Gerontol, 2002, PMID: 12577695). Single-institute; no independent RCT replication as of April 2026. | 2002 |
| Khavinson & Morozov — Longevity study | Comprehensive long-term human study / elderly subjects | Combination Thymalin + Epitalon protocols associated with approximately 2.0-fold decrease in mortality over 6-year follow-up vs. controls; immune and endocrine function improvements documented. (Neuro Endocrinol Lett, 2003, PMID: 14523363). Same single-institute caveat applies. | 2003 |
| Glu-Trp dipeptide — Carcinogenesis study | In vivo (female rats, 12 months SC); n=44 treated vs. n=32 control | L-Glu-L-Trp SC (5 µg/rat 5x/week for 12 months): activated T-cell differentiation, T-cell recognition of peptide-MHC complexes, neutrophil chemotaxis and phagocytosis; reduced spontaneous tumor development vs. saline controls. Well tolerated. (Biogerontology; Khavinson/Morozov) | 2001 |
| Thymalin in severe COVID-19 (PMC8654498) | Elderly research subjects with severe COVID-19 and lymphopenia | Thymalin group: faster lymphopenia reversal; recovery in CD4+, CD3+HLA-DR+, B-cell, and NK-cell subpopulations vs. control. GI or systemic adverse events not prominently reported. Suggests thymic peptide bioregulation may have acute immunorestorative applications beyond chronic aging contexts. | 2021 |
How Does Thymalin Compare to Other Thymic and Immune Research Peptides?
| Parameter | Thymalin (Glu-Trp) | Thymosin Alpha-1 | LL-37 | Epitalon (AEDG) |
|---|---|---|---|---|
| Mechanism Level | Upstream: thymic organ function; T-cell maturation/output from thymus; thymocyte differentiation support | Downstream: mature T-cell, NK-cell, and dendritic-cell activation; TLR-mediated innate/adaptive bridge | Innate: direct antimicrobial; AMP; membrane disruption; innate immune activation | Epigenetic/telomere: telomerase (hTERT); AANAT/melatonin; circadian; not immune-primary |
| Structure | Dipeptide: L-Glu-L-Trp (Glu-Trp; MW ~332 Da); minimal active thymic sequence | 28-AA peptide; N-terminally acetylated (Ac-Ser); MW ~3,108 Da; isolated from thymosin fraction 5 (Goldstein 1977) | 37-AA cathelicidin AMP; MW ~4,493 Da; human host defense peptide | 4-AA tetrapeptide (AEDG); MW ~390 Da; Khavinson pineal bioregulator |
| Primary Research Target | Immunosenescence; thymic involution; T-cell output restoration; CD4/CD8 ratio; NK cell numbers | T-cell proliferation; NK cytotoxicity; dendritic cell maturation; antiviral and antifungal immunity; TLR9/STING activation | Antimicrobial (bacteria, fungi, viruses); immunomodulatory; wound healing; epithelial barrier | Telomerase activation; pineal melatonin; circadian gene expression; longevity biology |
| Evidence Base | Khavinson group (single-institute); some human longevity data (PMID: 12577695, 14523363); COVID-19 lymphopenia data (PMC8654498) | research-grade forms in some countries (thymalfasin; Zadaxin®); Phase 2/3 data in HBV, HCV, sepsis, cancer immunotherapy | Endogenous human AMP; preclinical antimicrobial data; wound healing models; no FDA approval | Khavinson group (single-institute); telomerase data in human somatic cells; longevity animal data |
| Khavinson System | Yes — thymus-targeted bioregulator; often combined with Epitalon in Khavinson protocols | No — different research tradition (Goldstein, GWU) | No | Yes — pineal-targeted; often combined with Thymalin |
| YPB SKU | YPB.280 — see product | YPB.228 — see guide | YPB.271 — see guide | YPB.253 — see guide |
Thymalin and Thymosin Alpha-1 are the two thymus-derived immune peptide families in the YPB catalog but operate at entirely different levels of the immune system. Thymalin targets thymic organ function — upstream T-cell production and maturation. Thymosin Alpha-1 (see the Thymosin Alpha-1 Research Guide) directly activates mature peripheral immune effector cells. Epitalon (see the Epitalon Research Guide) is the Khavinson pineal-targeted companion bioregulator, which was used alongside Thymalin in the published longevity protocols.
What Should Researchers Know About Thymalin Form, Stability, and Handling?
Critical: Confirming the Form (Glu-Trp Dipeptide vs. Polypeptide Complex)
The most important quality consideration for Thymalin research is confirming the exact form of the compound. The original “Thymalin” is a heterogeneous polypeptide complex from bovine thymus (MW 1,000–10,000 Da; heterogeneous HPLC profile). The identified active minimum sequence is the synthetic dipeptide L-Glu-L-Trp (“Thymogen®” in compound form; MW ~332 Da; a single well-defined compound with a clean HPLC profile). Research-grade “Thymalin” in synthetic peptide catalogs is typically the Glu-Trp dipeptide form — researchers should confirm this in the COA by verifying: (1) molecular weight (~332 Da for Glu-Trp dipeptide); (2) amino acid composition (Glu + Trp); (3) clean single-peak HPLC profile confirming a defined compound rather than a heterogeneous complex. All YPB Thymalin batches include lot-traceable COA documentation through the COA Library.
Tryptophan Photosensitivity
The Trp residue in L-Glu-L-Trp is susceptible to oxidative degradation (the same photosensitivity as the Trp residues in GHRP-6). Protect lyophilized and reconstituted Thymalin from light and UV exposure. Oxidized Trp products would appear at higher MW in MS and represent biologically inactive degradation products. Store in amber vials where possible.
Storage
Lyophilized: −20°C for up to 24 months. Reconstituted: 2–8°C, use within 14 days. Given the short Glu-Trp dipeptide structure, reconstituted stability is modest; single-use aliquots from lyophilized stock minimize degradation from repeated freeze-thaw cycles.
Key Research Findings
- Thymic involution context: By age 50, ~85% of thymic tissue replaced by adipose; by age 70, naïve T-cell output reduced ~95% vs. young adult. This is the biological basis for Thymalin’s research rationale: address the thymic decline that is the upstream root of immunosenescence.
- Active component: L-Glu-L-Trp (Glu-Trp; MW ~332 Da): Minimal active dipeptide isolated from the original Thymalin bovine polypeptide complex via HPLC fractionation; basis of Thymogen® compound. Research-grade Thymalin is typically the synthetic Glu-Trp form — confirm in COA at ~332 Da.
- Khavinson longevity human data (PMID: 12577695; 14523363): 6–8 year follow-up; ~2.0-fold mortality decrease in Thymalin + Epitalon group vs. controls; improved T-cell markers, CD4/CD8 ratio, NK cell activity. Most compelling clinical evidence for Thymalin but same single-institute caveat as all Khavinson data.
- COVID-19 lymphopenia reversal (PMC8654498): Faster restoration of CD4+, CD3+HLA-DR+, B-cell, and NK-cell populations in severe COVID-19 elderly research subjects — suggests acute immunorestorative application beyond chronic aging contexts.
- Upstream mechanism vs. Thymosin Alpha-1 downstream: Thymalin supports thymic T-cell production (factory); Thymosin Alpha-1 activates circulating mature immune effectors (workers). Complementary, not redundant.
- Glu-Trp carcinogenesis data (Biogerontology): Reduced spontaneous tumor development in female rats over 12-month SC protocol; proposed immune surveillance mechanism via T-cell competence restoration.
- No independent international RCT: All clinical evidence from Khavinson group (St. Petersburg); no independent Western-standard RCT as of April 2026. Research protocols should document this limitation.
- Trp photosensitivity: Single Trp residue susceptible to oxidative degradation; protect from light; confirm absence of higher-MW Trp oxidation products in COA MS data.
Browse the Full Research Catalog
Market Demand and Research Interest
| Demand Indicator | Thymalin Data Point |
|---|---|
| Search context | Thymic bioregulator; immunosenescence research; Khavinson peptide series; longevity immune support |
| Key publications | Khavinson & Morozov (2002) Adv Gerontol (PMID: 12577695); Khavinson & Morozov (2003) Neuro Endocrinol Lett (PMID: 14523363); COVID-19 data (2021, PMC8654498) |
| Unique catalog position | Only thymus-targeted upstream immune bioregulator in YPB catalog; addresses immunosenescence at the level of T-cell production rather than mature cell activation |
| Khavinson catalog complement | Natural companion to Epitalon (used together in published longevity protocols) and Pinealon in the Khavinson bioregulator system |
| COVID-19 acute relevance | Published data in acute lymphopenia/immunocompromised states broadens research interest beyond chronic aging context |
| Keyword difficulty range | Very low (KD <5); niche longevity/immune research audience |
How Can Researchers Offer Thymalin Under Their Own Brand?
Wholesale Pricing & Margin Analysis
| SKU | Compound | Premier ($497/mo) | Core ($297/mo) | Suggested MSRP | Premier Margin |
|---|---|---|---|---|---|
| YPB.280 (RUO) | Thymalin (L-Glu-L-Trp) | TBC Premier | TBC Core | TBC | TBC at Premier tier |
Contact the YPB team for confirmed Premier and Core tier pricing. Use the YPB Profit Calculator to model projected revenue. White-label brands offering the complete Khavinson bioregulator catalog — Thymalin (YPB.280; thymus), Epitalon (YPB.253; pineal), and Pinealon (YPB.273; CNS) — deliver a mechanistically coherent longevity research toolkit that mirrors the compound combination used in the published Khavinson long-term human studies. Adding Thymosin Alpha-1 creates a complete thymic immune research catalog covering both upstream (Thymalin) and downstream (Thymosin Alpha-1) immune biology. Download the full catalog for all immune and longevity category pricing.
Methodology & Data Sources
Methodology & Data Sources
Scientific literature: PubMed searched for “thymalin,” “L-glutamyl-L-tryptophan,” “Glu-Trp thymic,” “Thymogen peptide,” and “thymic bioregulator Khavinson.” Search conducted through April 2026.
Key sources: Khavinson & Morozov (2002) Adv Gerontol (PMID: 12577695); Khavinson & Morozov (2003) Neuro Endocrinol Lett (PMID: 14523363); PMC8654498 (COVID-19 lymphopenia); Biogerontology (Glu-Trp carcinogenesis in rats; Khavinson/Morozov); general thymic involution and immunosenescence literature.
Limitations: All Thymalin clinical evidence originates from the Khavinson group (St. Petersburg Institute of Bioregulation and Gerontology); no independent international RCT replication as of April 2026. The molecular mechanism (direct peptide modulation of thymic epithelial gene expression) is proposed from in vitro data but has not been definitively established by independent structural/molecular studies. Thymogen® (Glu-Trp) is approved in Russia; Not FDA-approved for human use. Investigational/research compound (RUO). This article is for educational purposes only.
References
- Khavinson, V. K., & Morozov, V. G. (2002). Geroprotective effect of thymalin and epitalon peptide bioregulators. Adv Gerontol, 10, 74–84. PMID: 12577695
- Khavinson, V. K., & Morozov, V. G. (2003). Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett, 24(3–4), 233–240. PMID: 14523363
- Khavinson, V., Morozov, V., et al. (2001). Immunomodulatory synthetic dipeptide L-Glu-L-Trp slows aging and inhibits spontaneous carcinogenesis in rats. Biogerontology, 2(2), 95–100.
- Linkova, N., Khavinson, V., et al. (2021). Thymalin: activation of differentiation of human hematopoietic stem cells. Stem Cell Rev Rep. (COVID-19 context; PMID: 33575961)
- Khavinson, V. K., et al. (2021). Peptide compound Thymalin regulates immune status in severe COVID-19 older research subjects. Adv Gerontol, 11(4), 368–376. PMC8654498.
- Goldstein, A. L., Low, T. L. K., McAdoo, M., McClure, J., Thurman, G. B., Rossio, J., Lai, C. Y., Chang, D., Wang, S. S., Harvey, C., Ramel, A. H., & Meienhofer, J. (1977). Thymosin α1: isolation and sequence analysis of an immunologically active thymic polypeptide. Proc Natl Acad Sci USA, 74(2), 725–729. (Thymosin Alpha-1 historical context for comparison.)
- Ershler, W. B., & Keller, E. T. (2000). Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu Rev Med, 51, 245–270. (Immunosenescence context.)
- Goronzy, J. J., & Weyand, C. M. (2013). Understanding immunosenescence to improve responses to vaccines. Nat Immunol, 14(5), 428–436. (Thymic involution and T-cell pool context.)
- Zhu, X., Gui, J., Deem, J. L., & Bhatt, D. L. (2023). T cell development and thymic involution. (General thymic biology context.)
Frequently Asked Questions
Thymalin is a thymic peptide bioregulator developed by Khavinson and Morozov (St. Petersburg, 1981), originally isolated from bovine calf thymus as a polypeptide complex. The identified active component is the dipeptide L-Glu-L-Trp (L-glutamyl-L-tryptophan; MW ~332 Da; basis of Thymogen®). In research models, Thymalin targets thymic organ function: modulating gene expression in thymic epithelial cells and thymocytes to support T-cell differentiation through DN → DP → SP developmental stages, with documented downstream improvement in CD3+, CD4+, CD4/CD8 ratio, and NK cell activity in aged subjects (Khavinson group publications; single-institute; PMID: 12577695, 14523363). Primary research applications: immunosenescence reversal, thymic involution biology, T-cell differentiation research, longevity immune studies. Published longevity data: ~2.0-fold mortality decrease at 6-year follow-up in Thymalin + Epitalon protocols. COVID-19 lymphopenia reversal also documented (PMC8654498). Not FDA-approved for human use. Investigational/research compound (RUO). Research Use Only (RUO). Updated April 2026.
Thymalin (Glu-Trp dipeptide) and Thymosin Alpha-1 (28-AA peptide; Ac-Ser-N-terminal; isolated by Goldstein at GWU in 1977 from thymosin fraction 5) both involve thymic peptide biology but operate at entirely different levels of the immune system. Thymalin targets the thymic microenvironment and thymocyte development — it works upstream at the thymic factory level, aiming to restore T-cell maturation and output from the thymus itself. The research question Thymalin addresses is: “Can restoring thymic function increase naïve T-cell production in aged tissue?” Thymosin Alpha-1 operates downstream of the thymus, directly activating mature peripheral immune effector cells — T cells (proliferation), NK cells (cytotoxicity), and dendritic cells (maturation and antigen presentation) — via toll-like receptor pathways and cytokine induction. The research question Thymosin Alpha-1 addresses is: “Can we directly stimulate the existing circulating immune cells to be more functional?” The two mechanisms are complementary rather than competing: Thymalin addresses production deficiency (fewer naïve T cells made); Thymosin Alpha-1 addresses functional deficiency (existing T cells and NK cells underperforming). In the Khavinson longevity research context, Thymalin is specifically used; in the international compound and clinical trial context, Thymosin Alpha-1 has broader regulatory approval history (Zadaxin® in multiple countries).
The thymus is the organ where all T-cell education occurs — T-cell precursors from bone marrow must pass through the thymic selection process to become functional naïve T cells. Thymic involution (progressive replacement of functional thymic tissue with adipose) begins after puberty and by age 50 has reduced functional thymic volume to approximately 15% of peak. Naïve T-cell output declines proportionally. The downstream consequences are measurable and well-documented: T-cell receptor (TCR) repertoire narrows as the naïve T-cell pool is not replenished with newly educated cells; the peripheral T-cell compartment becomes dominated by exhausted and memory cells with restricted antigen specificity; responses to novel pathogens, neoantigens, and vaccines become impaired. This progressive adaptive immune narrowing is a primary driver of increased susceptibility to infection, cancer, and reduced vaccine efficacy in older adults — defining immunosenescence as a major aging biology target. Thymalin research addresses this by targeting the thymic involution process upstream, rather than trying to supplement or activate the downstream pool of increasingly restricted T cells.
The original Thymalin was prepared as a polypeptide complex from bovine calf thymus tissue: a heterogeneous mixture of short peptides (2–8 amino acids; MW ranging 1,000–10,000 Da) with a broad HPLC profile. Through fractionation studies, the minimal active sequence was identified as the dipeptide L-Glu-L-Trp (L-glutamyl-L-tryptophan; MW ~332 Da). This dipeptide was synthesized and developed into the compound Thymogen®, approved in Russia. Research-grade “Thymalin” in modern synthetic peptide catalogs is typically the synthetic Glu-Trp dipeptide form rather than the original heterogeneous bovine extract. The key practical difference for researchers: the synthetic Glu-Trp dipeptide has a defined single molecular weight (~332 Da), clean HPLC profile, and predictable identity; the polypeptide complex has heterogeneous MW and variable component ratios. Researchers should confirm the form in the COA: MS at ~332 Da and Glu + Trp amino acid composition confirms the synthetic dipeptide form.
Thymalin research carries three important limitations that should be documented in research protocols. First, all clinical evidence originates from the Khavinson group at the St. Petersburg Institute of Bioregulation and Gerontology; no independent replication by international research groups as of April 2026. The same single-institute limitation applies to all Khavinson peptide bioregulator data (including Epitalon). Second, the clinical study designs (6–8 year follow-up in elderly subjects) do not meet current Western RCT standards for subject randomization, blinding, sample size, and statistical analysis rigor in most cases; the longevity data, while compelling in direction, cannot be considered established by evidence-based compound standards. Third, the proposed molecular mechanism (direct dipeptide modulation of thymic epithelial gene expression) is supported by in vitro data but has not been independently confirmed at the structural level. These limitations do not invalidate Thymalin as a research tool but should be stated explicitly in protocols and publications. Researchers approaching Thymalin biology for the first time are working with a relatively limited international evidence base that warrants further independent study.
Yes. YourPeptideBrand.com provides white-label dropship for Thymalin as YPB.280 (Research Use Only). White-label storefronts include pre-built RUO-compliant product pages with thymic bioregulator mechanism descriptions, immunosenescence biology context, Khavinson protocol history (clearly framed as single-institute research, not Western-standard RCT data), and COA library links. Contact the YPB team for confirmed Premier and Core pricing, and use the profit calculator to model projected revenue. Offering Thymalin alongside Epitalon creates the core Khavinson bioregulator pair used in the published longevity studies.
Every Thymalin batch includes a lot-specific COA: HPLC purity (≥98%), MS confirmation at ~332 Da (L-Glu-L-Trp dipeptide form; confirms the synthetic Glu-Trp active component rather than the original heterogeneous polypeptide complex), amino acid composition (Glu + Trp), endotoxin (<1 EU/mg), TAMC, and TYMC. The Trp residue is susceptible to oxidative degradation; an oxidized Trp product would appear at MW+16 (~348 Da) in MS. Any significant 348 Da peak in the MS indicates Trp oxidation and represents a quality concern for the batch. All lots are traceable through the batch-specific COA library.
Thymalin and Epitalon are the two most studied compounds in the Khavinson bioregulator system and were used together in the published longevity protocols. Their mechanisms are organ-specific and non-overlapping: Thymalin targets the thymus (T-cell immune function and immunosenescence); Epitalon targets the pineal gland (telomerase activation, AANAT/melatonin synthesis, circadian regulation). Position them as the “Khavinson longevity pair” — the two-compound protocol that appears in the published 6–8 year human follow-up data. For catalog content, Thymalin serves the immune aging research audience (immunologists, aging immunologists, T-cell biologists); Epitalon serves the longevity/telomere/circadian biology audience. There is meaningful overlap in the aging research buyer community, making cross-referencing between the two guides and product pages natural. Adding Thymosin Alpha-1 creates the complete thymic immune catalog: upstream thymic function (Thymalin) + downstream mature immune cell activation (Thymosin Alpha-1) from a single immune biology buyer audience.
Key Takeaways
Research Takeaways
- Thymic involution is the upstream root of immunosenescence: By age 50, ~85% of thymic tissue lost; naïve T-cell output depleted ~95% by age 70. TCR repertoire narrows; adaptive immune responses to novel antigens impaired.
- Active component: L-Glu-L-Trp (MW ~332 Da): Minimal active sequence isolated from original bovine polypeptide complex; confirm at ~332 Da in COA. Original Thymalin complex is heterogeneous (MW 1,000–10,000 Da).
- Upstream thymic mechanism vs. Thymosin Alpha-1 downstream: Thymalin supports T-cell production from the thymus; Thymosin Alpha-1 activates mature peripheral immune effectors. Complementary not redundant.
- Khavinson longevity data (PMID: 12577695; 14523363): ~2.0-fold mortality decrease at 6-year follow-up in Thymalin + Epitalon protocols; improved CD3+, CD4+, CD4/CD8, NK activity. Compelling directional data; same single-institute caveat as all Khavinson group studies.
- COVID-19 lymphopenia data (PMC8654498): Faster lymphocyte recovery in severe COVID-19 elderly research subjects; acute immunorestorative application documented.
- Trp oxidation COA check: Oxidized Trp at MW+16 (~348 Da) is a quality indicator; protect from light; any significant 348 Da peak indicates batch quality concern.
- No independent international RCT: All clinical evidence from Khavinson group; document limitation in research protocols.
Business Takeaways
- Khavinson longevity pair: Thymalin (YPB.280) + Epitalon (YPB.253) = the two-compound combination used in the published Khavinson long-term longevity studies; natural catalog pairing for the aging research audience.
- Complete thymic immune catalog: Thymalin (upstream) + Thymosin Alpha-1 (downstream) covers the full thymic immune biology spectrum from a single buyer audience.
- Niche but high-intent audience — immunosenescence and thymic biology researchers are a well-defined, growing segment as longevity research investment accelerates.
- Contact YPB for confirmed pricing on YPB.280.
Ready to add Thymalin to your research catalog? Book a consultation with the YPB team.
No laboratory research studies found for ”thymalin”